News
ASMB
29.95
+10.68%
2.89
Assembly Biosciences GAAP EPS of -$0.20 beats by $0.45, revenue of $13.37M beats by $6.92M
Seeking Alpha · 2h ago
*Assembly Biosciences 2Q Rev $13.4M >ASMB
Dow Jones · 2h ago
*Assembly Biosciences: Cash Runway Projected Into 2029 >ASMB
Dow Jones · 2h ago
Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate
Benzinga · 2h ago
*Assembly Biosciences 2Q Loss/Shr 20c >ASMB
Dow Jones · 2h ago
*Assembly Biosciences 2Q Loss $3.86M >ASMB
Dow Jones · 2h ago
Assembly Biosciences: Q2 Earnings Snapshot
Barchart · 7h ago
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
NASDAQ · 3d ago
Weekly Report: what happened at ASMB last week (0803-0807)?
Weekly Report · 3d ago
Weekly Report: what happened at ASMB last week (0727-0731)?
Weekly Report · 08/03 09:20
Weekly Report: what happened at ASMB last week (0720-0724)?
Weekly Report · 07/27 09:21
Weekly Report: what happened at ASMB last week (0713-0717)?
Weekly Report · 07/20 09:20
Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates
Seeking Alpha · 07/18 10:10
Weekly Report: what happened at ASMB last week (0706-0710)?
Weekly Report · 07/13 09:21
Weekly Report: what happened at ASMB last week (0629-0703)?
Weekly Report · 07/06 09:22
Weekly Report: what happened at ASMB last week (0622-0626)?
Weekly Report · 06/29 09:20
Health Care had the best week vs. the S&P 500 on record
Seeking Alpha · 06/26 20:59
Weekly Report: what happened at ASMB last week (0615-0619)?
Weekly Report · 06/22 09:23
Assembly Biosciences Is Maintained at Outperform by Mizuho
Dow Jones · 06/15 17:27
Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45
Benzinga · 06/15 17:17
More
Webull provides a variety of real-time ASMB stock news. You can receive the latest news about Assembly Bioscie through multiple platforms. This information may help you make smarter investment decisions.
About ASMB
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).